Acrivon Therapeutics (ACRV) Long-Term Investments (2022 - 2025)

Acrivon Therapeutics (ACRV) has reported Long-Term Investments for 4 consecutive years, with $5.1 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Long-Term Investments fell 66.81% year-over-year to $5.1 million; the TTM figure through Sep 2025 stood at $5.1 million (down 66.81% YoY), while the FY2024 annual figure was $5.1 million, changed N/A from the prior year.
• Long-Term Investments declined to $5.1 million in Q3 2025 per ACRV's latest filing, from $10.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $41.9 million in Q4 2022 and bottomed at $5.1 million in Q4 2024.
• Historically, Long-Term Investments has averaged $21.5 million across 4 years, with a median of $15.3 million in 2024.
• On a YoY basis, Long-Term Investments climbed as much as 66.81% in 2025 and fell as far as 74.44% in 2025.
• Acrivon Therapeutics' Long-Term Investments stood at $41.9 million in 2022, then retreated by 6.22% to $39.3 million in 2023, then plunged by 87.04% to $5.1 million in 2024, then climbed by 0.37% to $5.1 million in 2025.
• Business Quant data shows ACRV's Long-Term Investments at $5.1 million in Q3 2025, $10.2 million in Q2 2025, and $15.2 million in Q1 2025.